Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir)

  1. José A. Esté1,2,
  2. Cecilia Cabrera1,
  3. Dominique Schols2,
  4. Peter Cherepanov2,
  5. Arantxa Gutierrez1,
  6. Myriam Witvrouw2,
  7. Christophe Pannecouque2,
  8. Zeger Debyser2,
  9. Robert F. Rando3,
  10. Bonaventura Clotet1,
  11. Jan Desmyter2 and
  12. Erik De Clercq2
  1. 1Institut de la Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (J.A.E., C.C., A.G., B.C.), 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium (J.A.E., D.S., P.C., M.W., C.P., Z.D., J.D., E.D.C.), and 3Aronex Pharmaceutical Corporation, The Woodlands, Texas (R.F.R.).
     
    Next Section

    Abstract

    The human immunodeficiency virus (HIV) inhibitor AR177 (T30177, Zintevir) has been identified as a potent inhibitor of HIV integrasein vitro. The compound is currently the subject of clinical phase I/II trials. However, the primary target for the mechanism of action in vivo has not been identified unequivocally. We have found that AR177 inhibits syncytium formation between MOLT-4 cells and HUT-78 cells persistently infected with the HIV-1IIIB or NL4–3 strain, at a 50% effective concentration of 3 μg/ml, roughly 3-fold higher than the concentration required to inhibit HIV replication. Furthermore, flow cytometric analysis has shown that AR177 at 25 μg/ml interferes with the binding of the monoclonal antibody 9284 (directed to the V3 loop of gp120) on HIVIIIB-infected HUT-78 cells, pointing to inhibition of virus binding or virus fusion as the mechanism of action of AR177. To precisely characterize the site/target of intervention by AR177, we have selected HIV-1 (NL4–3) strains resistant to AR177. The binding of the AR177-resistant strain, unlike the parental HIV-1 NL4–3 strain, could not be inhibited by AR177. The resistant phenotype was associated with the emergence of mutations in the gp120 molecule. DNA sequence analysis revealed the presence of the K148E, Q278H, K290Q, and F391I mutations and a deletion of 5 amino acids (FNSTW) at positions 364–368 in the V4 region of the resistant strain but not of the wild-type HIV strain. Selection of resistant strains, although it takes a relatively long time to develop, may also select for strains with lower replicative capacity. No mutations were found in the integrase enzyme gene. Our data argue against HIV integrase being the primary target for the mechanism of anti-HIV action of AR177.

    AR177 (T30177) is an oligonucleotide of 17 nucleotides in length, composed only of deoxyguanosine and thymidine, with single phosphorothioate internucleoside linkages at its 5′ and 3′ ends (Rando et al., 1995). AR177 is a potent inhibitor of laboratory strains and clinical isolates of HIV-1 with 50% effective concentrations ranging between 0.025 and 3 μm in cell culture tests (Ojwanget al., 1995).

    AR177 has drawn a lot of attention because it has been shown to be one of the most potent inhibitors of the HIV integrase, prompting the development of this compound as a promising antiviral agent directed to a novel target of HIV replication. Indeed, we have shown that AR177 is able to inhibit integration of an oligonucleotide that mimics the integrase recognition sequence by inhibition of the first step of the integration reaction [that is, the formation of the initial stable complex between the integrase and the target DNA (Cherepanov et al., 1997)]. However, it remains to be shown that the potent activity on the integrase is responsible for the observed antiviral effect seen in the cell culture assays. Other oligonucleotides have been described as specific inhibitors of HIV envelope-mediated cell fusion and virus binding (Buckheit et al., 1994; Wyattet al., 1994). The polyanionic nature of these oligonucleotides, as in the case of dextran sulfate and heparin (Mitsuya et al., 1988) must play an important role in their inhibitory effect on HIV replication. To decipher unequivocally the mode of action of AR177, we have studied its possible interaction during early events of HIV replication. We have also selected a strain resistant to AR177. A critical parameter in the determination of clinical efficacy of antiviral drugs may be the rate of resistance development which can be estimated from experiments in vitro(De Vreese et al., 1996b). Also, the phenotype of the resistant strains may be different in infectivity and pathogenicity compared with the parental wild-type strain, which has important implications for the clinical response of the patients.

    Previous SectionNext Section

    Materials and Methods

    Compounds.

    DS, (Mr 5000) and heparin were purchased from Sigma (St. Louis, MO). The bicyclam derivative AMD3100 was synthesized at Johnson Matthey (West Chester, PA), as described elsewhere (Bridger et al., 1995). AZT was obtained from Wellcome (Greenford, UK). The oligonucleotides AR177 and ISIS5320 (Buckheit et al., 1994) were provided by author R.F.R. (Ojwang et al., 1995).

    Viruses, cells, antiviral activity assays, and cytotoxicity assays.

    Anti-HIV activity and cytotoxicity measurements in MT-4 cells (Harada et al., 1985) were based on viability of cells that had been infected or not infected with HIV-1 exposed to various concentrations of the test compound. After the MT-4 cells were allowed to proliferate for 5 days, the number of viable cells was quantified by a tetrazolium-based colorimetric method [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium method] as described by Pauwels et al. (1988). The HIV-1 NL4–3 strain is a molecular clone obtained from the National Institutes of Health (Bethesda, MD).

    Syncytium formation assay.

    HUT-78 cells (2 × 105 cells/ml) persistently infected with HIV-1IIIB were cocultured with MOLT-4 (clone 8) cells (1.8 × 106 cells/ml) in the presence of AR177. After 24 hr, the number of giant cells (syncytia) was recorded microscopically as described previously (Witvrouw et al., 1994).

    Immunofluorescence binding assays.

    The glycoprotein gp120 immunofluorescence assay has been described by Schols et al.(1990a). Briefly, HUT-78 cells persistently infected with HIV-1IIIB were incubated with AR177 or DS at the indicated concentrations for 20 min at room temperature. After incubation with anti-gp120 mAb (NEA 9284; DuPont De Nemours, Brussels, Belgium) for 50 min at 37° and subsequent staining with fluorescein isothiocyanate-conjugated F(ab)2 fragments of rabbit anti-mouse immunoglobulin antibody, the cells were fixed and analyzed by flow cytometry. For modulation of CD4 expression, MT-4 cells were incubated with 25 μg/ml AR177 or without compound and stained for flow cytometry analysis with mAb OKT4A (Ortho Diagnostics, Beerse, Belgium) directed to the CD4 receptor.

    Interaction of AR177 with recombinant gp120.

    Interaction between AR177 and gp120 was analyzed by surface plasmon resonance technology (BIAcore; Pharmacia, Uppsala, Sweden), following the procedures described previously (Fischer et al., 1995;Tamamura et al., 1996). Briefly, recombinant gp120 from the HIV-1IIIB strain (Intracell, London, UK) at 30 μg/ml was immobilized on the carboxymethylated surface of a sensor chip (CM5; Pharmacia), using a mixture of 400 mmN-ethyl-N-(3-dimethylaminopropyl) carbodiimide hydrochloride and 100 mmN-hydroxysuccinimide (Pharmacia). Excess, unreacted active groups on the surface were blocked using 1.0 m ethanolamine/HCl, pH 8.5, providing immobilized gp120 at 3097 response units (RU). Various concentrations of AR177 in 10 mm HEPES buffer, pH 7.4, containing 150 mm NaCl, 3.4 mm EDTA, and 0.005% surfactant P20 (Pharmacia) were injected onto the gp120 sensor chip surface at a flow rate of 5 μl/min. At the end of each run, the surface was regenerated with 10 mm glycine, pH 2.0.

    Selection of HIV-1 (NL4–3) mutant strains.

    MT-4 cells were infected with HIV-1 (NL4–3) in medium containing AR177 at 2 to 4 times the 50% effective concentration (EC50). Cultures were incubated at 37° until an extensive cytopathic effect was present (5–6 days). The culture supernatants were used for further passage in MT-4 cells in the presence of 2- to 5-fold increasing concentrations of AR177.

    Virus-binding assay.

    MT-4 cells (5 × 105) were infected with supernatant containing 1 × 105 pg of p24 antigen of either wild-type HIV-1 NL4–3 or AR177-resistant virus in the presence of different concentrations of the test compound. One hour after infection, cells were washed 3 times with PBS (Boehringer Mannheim, Barcelona, Spain) and p24 antigen bound to the cells was determined by a commercial test (Coulter, Barcelona, Spain).

    DNA sequence analysis.

    MT-4 cells were infected with wild-type HIV-1 or AR177-resistant HIV-1 and incubated at 37° for 4 days. The cells were washed in PBS and total DNA was extracted with a QUIAquick blood kit (Westburg, Leusden, The Netherlands). PCR amplification was performed with ULTMA DNA polymerase with proof-reading capacity (Perkin Elmer, Nieuwerkerk, The Netherlands). Fragments of appropriate molecular size were excised from agarose gel and purified. DNA sequencing was performed directly on the purified PCR product following the protocol provided by the ABI PRISM dye terminator-cycle sequencing kit and analyzed on an ABI PRISM 310 genetic sequencer (Perkin Elmer). The primer sets used for PCR amplification and sequence analysis are summarized in Table1.

    View this table:
    Table 1

    Primers used to amplify and sequence genes of the resistant NL4-3 virus strains

    Site-directed mutagenesis was performed using the Altered Sites IIin vitro mutagenesis system (Promega, The Netherlands). The V2-V5 region of gp120 was cloned in the pALTER-1 vector. An oligonucleotide (GACCCTTCAGTACTCCA-AGTACTATTAAACAGCTGTGTTGAATTAC) was used to introduce a deletion of 5 amino acids (FNSTW) in the V4 region of the cloned gp120. The mutated gp120 was recombined with the HIV-1 clone pNL4–3 by the marker rescue technique as described before (De Vreese et al., 1996a).

    Previous SectionNext Section

    Results

    Syncytium formation assay.

    AR177 inhibited giant cell (syncytium) formation between MOLT-4 cells and HUT-78 cells persistently infected with the HIV-1IIIB or NL4–3 at an EC50 of 3.0 μg/ml.

    Immunofluorescence binding assays.

    AR177 had no effect on the binding of anti-CD4 mAb (OKT4A) to the CD4 cell receptor (Fig.1A). However, AR177 at 25 μg/ml inhibited the binding of the mAb 9284 (directed to an epitope in the V3 loop region) to HUT-78 cells persistently infected with HIV-1 IIIB (Fig. 1B).

    Figure 1
    View larger version:
    Figure 1

    A, Flow cytometric histograms of the binding of anti-gp120 mAb (9284) on HUT-78 cells persistently infected with HIV-1 IIIB. Histograms: a, fluorescence of infected cells incubated only with RaM-IgGF(ab′)2-fluorescein isothiocyanate; b, specific fluorescence of the infected cells; c and d present the infected cells incubated with DS (25 μg/ml) and AR177 (25 μg/ml), respectively. B, Binding of OKT4A mAb to MT-4 cells in the absence (b) or presence of AR177 (25 μg/ml) (c). Histograma, control fluorescence of the isotype mAb.

    Interaction of AR177 with recombinant gp120.

    After various concentrations of AR177 were injected onto the gp120-immobilized sensor chip, we obtained the sensorgrams shown in Fig.2. AR177 showed a dose-dependent interaction with the immobilized gp120. Association with the gp120 was rapid, followed by a plateau (equilibrium) and then a gradual decrease (dissociation) after the end of the injection. The association (Ka) and dissociation (Kd) constants were calculated to beKa = 1.65 [m−1s−1 ] andKd = 0.0156 [s−1]. In a similar experiment, the bicyclam AMD3100 (125 μg/ml) did not bind to the recombinant gp120.

    Figure 2
    View larger version:
    Figure 2

    Sensorgrams obtained after injection of AR177 onto immobilized gp120. The concentrations of AR177 are 1.6, 8, 40, and 200 μg/ml. Arrows, start and end of the injection.

    Selection of HIV-1 (NL4–3) mutant strains.

    HIV-1 strains resistant to AR177 were raised in MT-4 cells. HIV-1 (NL4–3) was able to grow in the presence of AR177 at 300 μg/ml after 33 passages (182 days). The EC50 of AR177 for this resistant strain was >125 μg/ml. The HIV-1 (NL4–3) wild-type strain that was passaged in MT-4 cells for the same period of time remained sensitive to AR177 (EC50 = 0.6 μg/ml). The AR177- resistant virus was partially cross-resistant to DS5000 (34-fold, EC50 = 23.8 μg/ml), heparin (20-fold, EC50=3.9 μg/ml), and the oligonucleotide ISIS5320 (Buckheit et al., 1994) (>50-fold) but remained as sensitive to the bicyclam AMD3100 as the wild-type strain (Table2).

    View this table:
    Table 2

    Anti-HIV activity of different compounds against wild-type HIV-1 and AR177-resistant HIV-1.

    DNA sequence analysis.

    We have identified several mutations in the gp120 gene sequence of the AR177-resistant strain that were not present in the wild-type strain (Table3). Two of these mutations are located in the V3 loop region: Q278H and K290Q. The first one corresponds to a mutation also found in the HIV-1 NL4–3 strains resistant to DS (17) and the bicyclam AMD3100 (De Vreese et al., 1996a). Also, a deletion of 5 amino acids at position 364 to 368 (in the V4 loop) was detected in the AR177-resistant strain (Fig.3). No mutations were found in the sequence of the integrase gene of the AR177-resistant strain when compared with the wild-type strain (Cherepanov et al., 1997).

    View this table:
    Table 3

    Mutations in the gp120 of AR177-resistant NL4-3 strain

    Figure 3
    View larger version:
    Figure 3

    Inhibition of virus binding to MT-4 cells. The cells were incubated with 1 × 105 pg of p24 antigen of wild-type HIV-1 NL4–3 in the presence of varying concentrations of AR177 (◆), DS (▴), or AR177-resistant HIV-1 in the presence of AR177 (▪) or DS (×). After 1 hr incubation, cells were washed in PBS an p24 antigen bound to the cells was determined by a commercial test.

    Virus-binding assay.

    AR177 and DS inhibited the detection of p24 antigen bound to MT-4 cells after 1 hr incubation of cells with wild-type virus supernatant. The 50% inhibitory concentrations (IC50) were 2.4 μg/ml and 0.8 μg/ml for AR177 and DS, respectively. P24 antigen bound to MT-4 cells was detected in cells cultured with AR177-resistant supernatant; however, AR177 or DS did not significantly inhibit virus binding (as measured as bound p24 antigen) (Fig. 4). Similarly, the reverse transcriptase inhibitor AZT (1.0 μg/ml) or the fusion inhibitor AMD3100 (125 μg/ml) did not inhibit the binding of HIV to MT-4 cells when wild-type or AR177-resistant virus were used (data not shown).

    Figure 4
    View larger version:
    Figure 4

    Amino acid sequence of the V4 loop of HIV-1 (Gallagher et al, 1995). Boxed amino acids (FNSTW), deletion found in the AR177-resistant strain.

    Mutagenesis of the V4 loop.

    Recombinant virus that carries the deletion in the V4 loop corresponding to amino acids FNSTW was recovered after transfection of the HIV-1/NL4–3/DV4 proviral DNA into MT-4 cells. The EC50 of AR177 for the recombinant virus was 0.4 μg/ml, roughly the same as the EC50 required for the wild-type HIV-1 NL4–3 strain. The recombinant virus was sensitive to AMD3100 (EC50 = 0.003 μg/ml) but partially cross-resistant to DS (25-fold).

    Previous SectionNext Section

    Discussion

    AR177 is a potent inhibitor of laboratory strains and clinical isolates of HIV-1 (Ojwang et al., 1995). The mode of action of this compound, which forms a guanosine-quartet structure, has been attributed in part to its anti-integrase activity. Mazumder et al. (1996) have postulated that “G-quartet structures may act as negative regulators of autointegration in vivo and that novel AIDS therapies could be based upon G-quartets as inhibitors of HIV integrase” We have shown that the bases for the anti-integrase activity of AR177 may be different from those of such polyanionic compounds as DS, prompting the use of AR177 as a tool to study the fundamental aspects of HIV integration and the molecular structure that determines the effect of AR177 on HIV integrase (Cherepanov et al., 1997).

    In cell culture, however, the primary target for AR177 seemed to be the envelope gp120 protein of HIV-1. The polyanionic nature of AR177 correlates well with that of other polyanionic compounds, such as DS and heparin. We have shown that AR177 interacts in a concentration-dependent manner with recombinant gp120. Furthermore, AR177 inhibits the binding of recombinant gp120 to CD4+ cells (Fig. 1) and inhibits syncytium formation (which can be interpreted as HIV-1 fusion with the cell membrane) at roughly the same concentration as needed for its HIV replication inhibitory activity. Thus, AR177 has a bimodal mechanism of action, namely inhibition of virus binding and inhibition of virus fusion, which both seem to be mediated by gp120 but may depend on distinct viral and cellular determinants.

    It is possible, however, that AR177 may be active at later step(s) of the virus replication cycle. One way to clearly identify the viral proteins targeted by an antiviral compound is the development of resistance to the compound in vitro. We have shown previously that HIV-1 strains that are resistant to inhibitors targeted at the binding/fusion step of replication can emerge after sequential passaging of the virions in cell culture in the presence of the antiviral compound (De Vreese et al., 1996a; Estéet al., 1997; Esté et al., 1996). Resistance to the activity of such compounds as dextran sulfate will arise if the virus is given sufficient time and enough selective pressure for the resistant virus to emerge. Resistance to the bicyclam AMD3100 and to dextran sulfate appear to be mediated by a combination of specific mutations in the gp120 molecule of the resistant HIV strains (De Vreese et al., 1996a; Esté et al., 1997).

    Here, we show that resistance to AR177 develops after 33 passages of HIV-1/NL4–3 in MT-4 cells in the presence of increasing concentrations of the compound. The resistant virus was able to replicate in the presence of AR177 at concentrations up to 125 μg/ml. DNA sequence analysis of the gp120 coding region showed the emergence of mutations in the AR177-resistant strain that were not present in the wild-type strain. No mutations were detected in the DNA coding region of the integrase.

    Although indirect, the data presented here represents strong evidence of gp120 as the molecular target of AR177, and it becomes clear that AR177 binds and interacts with the gp120 molecule. However, to directly challenge the functional importance of this interaction, we tested the binding of wild-type and AR177-resistant virus to CD4 positive cells in the absence or presence of compound. AR177 inhibited the binding of wild-type virus at roughly the same concentrations required for inhibition of syncytium formation or virus replication (4-fold higher) but was not able to significantly inhibit virus binding when AR177-resistant virus was used, even in the presence of concentrations up to 125 μg/ml. Agents that do not interact with the gp120 molecule, such as the reverse transcriptase inhibitor AZT or the CXCR-4 antagonist AMD3100 (Schols et al., 1997) did not inhibit the binding of either wild-type or AR177-resistant strains to CD -positive cells. We show that the gp120, which mediates the binding to the CD4 positive cells (Mitsuya et al., 1988; Gallagher et al., 1995), is indeed a binding target of AR177. The AR177-resistant strain, which expresses the mutant gp120, can now bind to CD4 positive cells in the presence of the compound, which suggests that the relevant mutant gp120 is not a functional binding target of AR177.

    It is noteworthy that the DNA sequence of the AR177-resistant strain revealed the emergence of mutations that appear also in the AMD3100-resistant and DS-resistant strains, namely mutation Q278H in the V3 loop and a deletion of 5 amino acids (FNSTW) at positions 364 to 368 in the V4 loop (Fig. 4). The AR177-resistant strain is partially cross-resistant to DS but not to AMD3100. This apparent discrepancy can be explained by (i) the fact that the deletion in the V4 loop, as seen in the mutagenesis experiments, is not sufficient to generate resistance to either AR177 or AMD3100 but confers partial (25-fold) resistance to DS; (ii) a longer time (up to 60 passages) and more mutations (up to 12) are required for resistance to AMD3100 to develop than for either AR177 or DS resistance; (iii) if each one of the mutations found in the AMD3100 strain are introduced in the wild-type strain by site-directed mutagenesis, the recovered virus remains sensitive to AMD3100 (De Vreese K, manuscript in preparation), Thus, while the Q278H mutation and the 364FNSTW368 deletion may not to be sufficient to induce resistance to either AR177 or AMD3100, they may be a necessary requirement for resistance to occur for binding and/or fusion inhibitors such as the bicyclams, sulfated polysaccharides, and polyanions (such as AR177) in general.

    Another interesting aspect of the resistance development to AR177 is that although the resistant virus was able to induce a clear cytopathic effect on MT-4 cells, the amount of p24 antigen required to induce the same cytopathic effect as the wild-type strain was up to 6-fold higher (data not shown). Similarly, the amount of bound virus, as measured as p24 antigen bound to MT-4 cells, was lower when AR177-resistant virus was used instead of wild-type virus. Although this phenomenon must be studied further, the data indicates that AR177 may select for strains with a lower replicative capacity or with lower pathogenicity.

    It is not impossible that further passage of the AR177-resistant strain in ever-increasing concentrations of AR177 could eventually lead to the emergence of mutations in the integrase gene. However, it should be pointed out that concentrations of AR177 higher than the ones used in our experiments could be toxic to the cell. Although G-quartet structures seem to be highly stable, an oligomer of this relatively high molecular mass (5400 Da) may not be readily internalized by the cell. If it were internalized, we imagine that not only might the integrase activity but also the reverse transcriptase activity serve as targets for the action of AR177, because AR177 seems to also inhibit reverse transcriptase in vitro (Ojwang et al., 1995).

    The HIV envelope gp120 has gained renewed interest as a potential target for chemotherapeutic intervention in view of recent reports that this molecule mediates the interaction of the virus, not only with its primary receptor, CD4, but also with the β-chemokine receptor, HIV’s second receptor (Cocchi et al., 1995; Feng et al., 1996; Dragic et al., 1996). Both binding and fusion of HIV to the cell seem to be mediated in part by the gp120 molecule. Polyanions, such as DS or AR177, interfere with both processes, which are clearly interrelated but may have different molecular determinants within the gp120 molecule. Further insight into the mechanism of action of such compounds as AR177 will aid our understanding of the molecular determinants of virus binding and virus fusion and of the role of the cellular receptors that permit this binding/fusion.

    Previous SectionNext Section

    Acknowledgments

    We thank Cindy Heens, Kristien Erven, Erik Fonteyn, and Sandra Claes for excellent technical assistance.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: Dr. José Esté, Fundació irsiCaixa, Retrovirology Laboratory, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain. E-mail:jaeste{at}ns.hugtip.scs.es

    • This work was supported in part by the Biomedical Research Program of the European Commission, the Janssen Research Foundation, and by grants from the Belgian Geconcerteerde Onderzoeksacties, the Belgian Nationaal Fonds voor Wetenschappelijk Onderzoek, and the Fundació irsiCaixa, Spain.

    • Abbreviations:
      HIV
      human immunodeficiency virus
      DS
      dextran sulfate
      AZT
      3-azido-3′-deoxythymidine
      mAb
      monoclonal antibody
      HEPES
      4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
      PBS
      phosphate-buffered saline
      PCR
      polymerase chain reaction
      • Received January 15, 1997.
      • Accepted September 30, 1997.
    Previous Section
     

    References

    1. ↵
      1. Bridger GJ,
      2. Skerlj RT,
      3. Thornton D,
      4. Padmanabhan S,
      5. Martellucci SA,
      6. Henson GW,
      7. Abrams MJ,
      8. Yamamoto N,
      9. De Vreese K,
      10. Pauwels R,
      11. De Clercq E
      (1995) Synthesis and structure-activity relationship of phenylenebis-(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effect of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 38:366–378.
      CrossRefMedlineWeb of Science
    2. ↵
      1. Buckheit RW,
      2. Roberson JL,
      3. Lackman-Smith C,
      4. Wyatt JR,
      5. Vickers TA,
      6. Ecker DJ
      (1994) Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS5320). AIDS Res Hum Retrovir 10:1497–1506.
      MedlineWeb of Science
    3. ↵
      1. Cherepanov P,
      2. Esté JA,
      3. Rando RF,
      4. Reekmans G,
      5. David G,
      6. De Clercq E,
      7. Debyser Z
      (1997) Interaction of human immunodeficiency virus-1 integrase with guanosine-quartet forming oligonucleotides. Mol Pharmacol 52:771–780.
      Abstract/FREE Full Text
    4. ↵
      1. Cocchi F,
      2. DeVico AL,
      3. Garzino-Demo A,
      4. Arya SK,
      5. Gallo RC,
      6. Lusso P
      (1995) Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science (Washington DC) 270:1811–1815.
      Abstract/FREE Full Text
    5. ↵
      1. De Vreese K,
      2. Kofler-Mongold V,
      3. Leutgeb C,
      4. Weber V,
      5. Vermeire K,
      6. Schacht S,
      7. Anné J,
      8. De Clercq E,
      9. Datema R,
      10. Werner G
      (1996a) The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 70:689–696.
      Abstract
    6. ↵
      1. De Vreese K,
      2. Reymen D,
      3. Griffin P,
      4. Steinkasserer A,
      5. Werner G,
      6. Bridger G,
      7. Esté J,
      8. James W,
      9. Henson GW,
      10. Desmyter J,
      11. Anné J,
      12. De Clercq E
      (1996b) The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res 29:209–219.
      CrossRefMedline
    7. ↵
      1. Dragic T,
      2. Litwin V,
      3. Allaway GP,
      4. Martin SR,
      5. Huang Y,
      6. Nagashima KA,
      7. Cayanan C,
      8. Maddon PJ,
      9. Koup RA,
      10. Moore JP,
      11. Paxton W
      (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667–673.
    8. ↵
      1. Esté JA,
      2. Schols D,
      3. De Vreese K,
      4. Van Laethem K,
      5. Vandamme AM,
      6. Desmyter J,
      7. De Clercq E
      (1997) Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol 52:98–104.
      Abstract/FREE Full Text
    9. ↵
      1. Esté JA,
      2. De Vreese K,
      3. Witvrouw M,
      4. Schmit JC,
      5. Vandamme AM,
      6. Anné J,
      7. Desmyter J,
      8. Henson GW,
      9. Bridger G,
      10. De Clercq E
      (1996) Antiviral activity of the bicyclam AMD3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res 29:297–307.
      CrossRefMedline
    10. ↵
      1. Feng Y,
      2. Broder CC,
      3. Kennedy PE,
      4. Berger EA
      (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (Washington DC) 272:872–877.
      Abstract
    11. ↵
      1. Fischer PB,
      2. Collin M,
      3. Karlsson GB,
      4. James W,
      5. Butters TD,
      6. Davis SJ,
      7. Gordon S,
      8. Dwek RA,
      9. Platt FM
      (1995) The α-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol 69:5791–5797.
      Abstract
    12. ↵
      1. Gallagher WR,
      2. Ball J,
      3. Garry J,
      4. Martin-Amedee A,
      5. Montelaro R
      (1995) A general model for the surface glycoprotein of HIV and other retroviruses. AIDS Res Hum Retrovir 11:191–202.
      MedlineWeb of Science
    13. ↵
      1. Harada S,
      2. Koyanagi Y,
      3. Yamamoto N
      (1985) Infection of HTLV-IIIB/LAV in HTLV-I-carrying cells MT-2 and MT-4: an application in a plaque assay. Science (Washington DC) 229:563–566.
      Abstract/FREE Full Text
    14. ↵
      1. Mazumder A,
      2. Neamati N,
      3. Ojwang JO,
      4. Sunder S,
      5. Rando RF,
      6. Pommier Y
      (1996) Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 35:13762–13771.
      CrossRefMedline
    15. ↵
      1. Mitsuya H,
      2. Looney DJ,
      3. Kuno S,
      4. Ueno R,
      5. Wong-Staal W,
      6. Broder S
      (1988) Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (Washington DC) 240:646–648.
      Abstract/FREE Full Text
    16. ↵
      1. Ojwang JO,
      2. Buckheit R,
      3. Pommier Y,
      4. Mazumder A,
      5. De Vreese K,
      6. Esté JA,
      7. Reymen D,
      8. Pallansch L,
      9. Lackman-Smith C,
      10. Wallace T,
      11. De Clercq E,
      12. McGrath M,
      13. Rando RF
      (1995) T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 39:2426–2435.
      Abstract
    17. ↵
      1. Pauwels R,
      2. Balzarini J,
      3. Baba M,
      4. Snoeck R,
      5. Schols D,
      6. Herdewijn P,
      7. Desmyter J,
      8. De Clercq E
      (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309–321.
      CrossRefMedlineWeb of Science
    18. ↵
      1. Rando RF,
      2. Ojwang J,
      3. Elbaggari A,
      4. Reyes JR,
      5. Tinder R,
      6. McGrath MS,
      7. Hogan ME
      (1995) Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J Biol Chem 270:1754–1760.
      Abstract/FREE Full Text
    19. ↵
      1. Schols D,
      2. Pauwels R,
      3. Desmyter J,
      4. De Clercq E
      (1990) Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 175:556–561.
      CrossRefMedlineWeb of Science
    20. ↵
      Schols D, Struyf S, Van Damme J, Esté JA, Henson G, and De Clercq E (1997) Inhibition of T-tropic HIV strains by selective antagonism of the chemokine receptor CXCR4. J Exp Med, in press..
    21. ↵
      1. Tamamura H,
      2. Otaka A,
      3. Murakami T,
      4. Ishihara T,
      5. Ibuka T,
      6. Waki M,
      7. Matsumoto A,
      8. Yamamoto N,
      9. Fuji N
      (1996) Interaction of an anti-HIV peptide T22, with gp120 and CD4. Biochem Biophys Res Commun 219:555–559.
      CrossRefMedline
    22. ↵
      1. Witvrouw M,
      2. Esté JA,
      3. Quiñones-Mateu M,
      4. Reymen D,
      5. Andrei G,
      6. Snoeck R,
      7. Ikeda S,
      8. Pauwels R,
      9. Bianchini N,
      10. Desmyter J,
      11. De Clercq E
      (1994) Activity of a sulfated polysaccharide extracted from the red seaweed Aghardiella tenera against human immunodeficiency virus and other enveloped viruses. Antiviral Chem Chemother 5:297–303.
    23. ↵
      1. Wyatt JR,
      2. Vickers TA,
      3. Roberson JL,
      4. Buckheit RW,
      5. Klimkait JT,
      6. De Baets E,
      7. Davis PW,
      8. Rayner B,
      9. Imbach JL
      (1994) Combinatorially selected guanosine -quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci USA 91:1356–1360.
      Abstract/FREE Full Text
    « Previous | Next Article »Table of Contents

    This Article

    1. Molecular Pharmacology February 1, 1998 vol. 53 no. 2 340-345
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 76 (5)
    1. Current Issue
    1. Alert me to new issues of Molecular Pharmacology